UBS Group’s Aehr Test Systems AEHR Stock Holding History

UBS Group’s Portfolio AEHR Stock Details AEHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-48,600	Closed	-$1.29M	–	9236
2023 Q4	$1.29M	Buy	+48,600	New	+$1.42M	﹤0.01%	4263

Other funds holding AEHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's AEHR Position: Q1 2026 in Review

UBS Group increased its Aehr Test Systems (AEHR) stake by 1.5% in Q1 2026, buying an estimated $116K and bringing the position to 246,763 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3461.

UBS Group first reported a position in AEHR in Q4 2014 and has held it in 30 quarters since. 191 funds tracked by Wall St. Rank hold AEHR as of Q1 2026.

UBS Group held 246,763 shares of Aehr Test Systems worth $9.15M as of Q1 2026.
UBS Group bought 3,634 Aehr Test Systems shares in Q1 2026, an estimated $116K.
Aehr Test Systems made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3461 holding.
UBS Group first reported a position in Aehr Test Systems in Q4 2014 and has held it in 30 quarters since.
191 funds tracked by Wall St. Rank held Aehr Test Systems as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.